HHS cleared BPC-157 for compounding. Three states forbid their doctors to prescribe it.

On Thursday, October 30, the Department of Health and Human Services published a notice in the Federal Register telling licensed pharmacies and physicians that the federal government will not act against them for compounding BPC-157, TB-500, KPV, MOTS-c, epitalon or semax, six peptides no regulator has approved. The notice says of itself that it does not establish any rights for any person and is not binding on HHS or the public. The obvious reading is that it binds the department and not you. The reading that matters more is the one the notice does not spell out: it binds no state. The policy's own conditions require a State-licensed pharmacy or a licensed physician, and every one of those licenses is issued, policed and revoked by a state board. In at least three states, those boards had already answered the question the policy raises, months before it was written, and their answer was no.

Three boards, one sentence

Between May and August 2026, the medical and pharmacy regulators of Alabama, Mississippi and South Carolina each issued a notice to their licensees about non-FDA-approved, "research-grade" peptides. They are strikingly alike; the Mississippi and South Carolina texts share whole paragraphs. All three turn on one sentence. Alabama's Board of Medical Examiners, May 26: under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient. South Carolina's Board of Medical Examiners, August 18: under no circumstances is it permissible for a physician to compound, administer, prescribe, or dispense research-grade or FDA-ineligible peptides to a patient. Mississippi's Board of Medical Licensure, Board of Nursing and Board of Pharmacy, jointly, August 19: Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non-FDA approved or research-grade peptide to a patient.

Three further points recur in each. Delegation does not help: a physician may not circumvent his or her duty of care to patients by permitting or delegating the purchase, administration, or dispensing of these drugs to nurse practitioners or physician assistants. Paperwork does not help: Patient consent forms purporting to identify a product as "research-grade" are ineffective and do not mitigate or eliminate the health care provider's professional or legal liability. And sourcing is policed at the state line: licensees must purchase all prescription products, drugs, and ingredients from an entity permitted by the state's Board of Pharmacy, and South Carolina adds that buying from an unpermitted facility is aiding and abetting unlicensed practice.

South Carolina's notice has a footnote the others lack. Category 2 peptides also should not be used in compounding as they are not approved for general human use outside of controlled research settings. Category 2 was where FDA had placed BPC-157, TB-500, KPV, MOTS-c, epitalon and semax until April of this year. The state board was telling its licensees, in August, not to compound the six substances the federal department would, in October, say it will not stop them compounding.

Ohio reached the same place by a different road. Its Board of Pharmacy has, over the past year, issued summary suspension orders and settlement agreements against clinics and distributors in which it characterized peptide products including BPC-157 as unapproved drugs not permitted to be compounded, and used their presence as grounds for immediate action against the license. That is a description from a law firm's review of the board's published orders; the orders themselves are public, and the pattern is not in dispute.

What this does to the policy

The HHS policy is a promise about one enforcer. It says the department will not act. It says nothing about the Alabama Board of Medical Examiners, because it cannot: the practice of medicine and pharmacy is licensed by the states, and a state board does not need a federal violation to discipline a licensee for conduct its own rules prohibit. A physician in Mobile who writes a prescription for compounded BPC-157 next week is not exposed to FDA. He is exposed to the board that told him in May that he may not do it under any circumstances, and the federal notice gives him nothing to show that board but a document that says it is not binding on anyone.

The policy's drafters knew this. The reported conditions include that compounders comply with applicable state law, and the Alliance for Pharmacy Compounding, which welcomed the notice on the day it was filed, said in the same statement that it would seek clarification from HHS and FDA on how the policy would be coordinated with state boards. There is nothing to coordinate. A federal decision not to prosecute does not amend a state's practice act, and no mechanism in the notice asks the states to do anything.

So the map of where the six peptides may now be compounded is not one map but fifty, and the department drew none of them. In states whose boards have said nothing, the policy opens a door that was arguably never locked from the federal side in practice. In states whose boards have spoken, the door is shut regardless. In the rest, the first disciplinary case will decide. Pharmacies that read the headlines and started taking prescriptions this week are relying on a promise from the one regulator that does not hold their license.

The line the states drew

What is most striking in the three notices is not the prohibition but the definition behind it. South Carolina: Research-grade peptides are manufactured strictly for laboratory or animal research. Mississippi and Alabama: research-grade peptides have not been tested, reviewed, or determined to be safe or effective for human use, and neither the provider nor the patient can fully assess, quantify, or understand the potential risks associated with the use of research-grade peptides, nor can they verify the contents of any vials.

That is the research-use line, drawn by regulators of medicine rather than by a seller of chemicals, and drawn more cleanly than the federal government has managed. A research-grade peptide is a laboratory material. It belongs in a laboratory, in the hands of someone who can characterize it, and its label is a description of what is known about it, not a disclaimer to be waived on a consent form. The boards reject the consent-form device in terms, which is what the Victorian coroner's findings on Richard Norton's death demonstrated in practice a week ago: a form that calls a vial "research-grade" changes nothing about the molecule and nothing about who is responsible.

The boards also put their finger on verification. Their objection is that neither party can verify the contents of any vials. That is true of a vial bought from a website with no certificate, no lot number and no laboratory behind it, and it is the right objection to make. It is the same objection this library makes of any supplier, and the reason the library spends so many pages on how a certificate is read and what it leaves out. Verification is a laboratory activity. The states are saying that a clinic is not a laboratory, and they are right.

The sourcing problem nobody has priced

Put the federal and state conditions side by side and a narrower consequence appears. The HHS policy, as reported, requires that the bulk peptide come from a manufacturer registered with FDA and operating under good manufacturing practice, named on the certificate. The state notices require that every ingredient come from an entity permitted by the state board of pharmacy. A bulk-peptide manufacturer in Asia, which is where most of this material is made, is rarely the first and almost never the second. The set of suppliers that satisfy both is small, and the price of material from it is not the price of research-grade powder. A pharmacy that meets every condition will be compounding BPC-157 from a very short list of sources at a cost the policy's champions have not discussed. A pharmacy that does not meet them is outside the policy, and inside its state board's definition of research-grade.

What to watch

• The next boards. Alabama, Mississippi and South Carolina acted before the policy; the question is which boards act after it, and in which direction. A board that adopts the federal conditions as its own would be the first to actually open the door.
• The clarification the pharmacists asked for. Whether HHS says anything at all about state law, and whether FDA, which has not spoken, says anything about the policy.
• The docket. Comments close November 13. As of this morning there are none.
• The first discipline. A licensee in a no-circumstances state who compounds under the policy and is called before the board will produce the first ruling on what the notice is worth, and it will be a state ruling.

Frequently asked questions

Does the HHS policy override a state board's prohibition?

No. It is a statement that the federal department will not take enforcement action. State boards license pharmacies and physicians under state law and discipline them under state rules; the notice says it binds no one and asks the states for nothing.

Which states have said licensees may not compound research-grade peptides?

Alabama (Board of Medical Examiners, May 26, 2026), South Carolina (Board of Medical Examiners, August 18, 2026) and Mississippi (Boards of Medical Licensure, Nursing and Pharmacy jointly, August 19, 2026), each in the words "under no circumstances". Ohio's Board of Pharmacy has reached the same position through enforcement orders.

Do those notices cover the six peptides in the HHS policy?

They cover non-FDA-approved and research-grade peptides generally, which includes all six. South Carolina's notice names Category 2 peptides specifically, which is where the six sat until April 2026.

Does a consent form calling the product research-grade protect a provider?

All three boards say it does not: such forms are ineffective and do not mitigate or eliminate the health care provider's professional or legal liability.

What does this change for research-labeled peptides?

Nothing in law. The state notices define research-grade material as made for laboratory research and keep it out of practice, which is the same line the research-use label draws. The question for any supplier of such material is whether its documentation lets a laboratory verify the contents, which is the objection the boards raise.

Sources & Further Reading

1. Alabama Board of Medical Examiners. Board Issues Official Notice Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides. Press release and notice to licensees, May 26, 2026, albme.gov.
2. Mississippi State Board of Medical Licensure, Mississippi Board of Nursing, Mississippi Board of Pharmacy. Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides. August 19, 2026, msbn.ms.gov.
3. South Carolina Board of Medical Examiners. Notice Concerning the Prescribing of Research-Grade Peptides and FDA-Ineligible Peptides. August 18, 2026, llr.sc.gov.
4. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. 91 FR 68526, October 30, 2026, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496.
5. Alliance for Pharmacy Compounding. Statement on the HHS peptide enforcement discretion policy, October 28, 2026, a4pc.org.
6. Frier Levitt. Peptides Under the Microscope: Recent FDA and State Enforcement Trends, 2026; review of the Ohio Board of Pharmacy's published summary suspension orders and settlement agreements involving peptide products.
7. regulations.gov, Docket HHS-OASH-2026-0496: two documents, no comments, as listed on the morning of November 1, 2026.

Cosmic Peptides. (2026, November 1). HHS cleared BPC-157 for compounding. Three states forbid their doctors to prescribe it.. Cosmic Peptides Research Library. Retrieved November 1, 2026, from https://cosmicpeptides.com/research/perspectives/the-policy-binds-no-state

@misc{cosmicpeptides_research_perspectives_the_policy_binds_no_state,
  author       = {{Cosmic Peptides}},
  title        = {HHS cleared BPC-157 for compounding. Three states forbid their doctors to prescribe it.},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/perspectives/the-policy-binds-no-state},
  urldate      = {2026-11-01},
  note         = {Last reviewed 2026-11-01}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - HHS cleared BPC-157 for compounding. Three states forbid their doctors to prescribe it.
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/01
UR  - https://cosmicpeptides.com/research/perspectives/the-policy-binds-no-state
Y2  - 2026/11/01
LA  - en
ER  -